OMEGA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.36 USD | +0.21% |
|
+9.51% | -21.59% |
| May. 06 | Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 16 | Omega Therapeutics CFO Joshua Reed to Depart | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 541.3 | 274.4 | 166 | 129.9 | - | - |
| Enterprise Value (EV) 1 | 335.8 | 169.6 | 166 | 2.914 | 98.96 | 16.36 |
| P/E ratio | -3.71 x | -2.67 x | -1.67 x | -1.91 x | -1.94 x | -1.85 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3,759 x | 132 x | 53.6 x | 31 x | 142 x | 4.8 x |
| EV / Revenue | 2,332 x | 81.8 x | 53.6 x | 0.69 x | 108 x | 0.61 x |
| EV / EBITDA | -5.2 x | -1.68 x | - | -0.03 x | -0.76 x | -0.11 x |
| EV / FCF | -5.68 x | -1.7 x | - | -0.03 x | -1.21 x | -0.14 x |
| FCF Yield | -17.6% | -58.9% | - | -3,157% | -82.9% | -697% |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 47,775 | 48,049 | 55,142 | 55,155 | - | - |
| Reference price 2 | 11.33 | 5.710 | 3.010 | 2.360 | 2.360 | 2.360 |
| Announcement Date | 3/10/22 | 3/1/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.144 | 2.073 | 3.094 | 4.197 | 0.9167 | 27.05 |
| EBITDA 1 | - | -64.64 | -101.2 | - | -91.72 | -129.8 | -150.2 |
| EBIT 1 | - | -66.03 | -102.8 | -100.3 | -85.31 | -106.6 | -154.2 |
| Operating Margin | - | -45,855.56% | -4,957.36% | -3,240.5% | -2,032.73% | -11,633.91% | -570.18% |
| Earnings before Tax (EBT) 1 | - | -68.28 | -102.7 | -97.43 | -78.12 | -95.43 | -138.9 |
| Net income 1 | -29.45 | -68.28 | -102.7 | -97.43 | -78.12 | -95.43 | -138.9 |
| Net margin | - | -47,416.67% | -4,954.22% | -3,148.93% | -1,861.43% | -10,410.21% | -513.45% |
| EPS 2 | -7.556 | -3.050 | -2.140 | -1.800 | -1.238 | -1.216 | -1.275 |
| Free Cash Flow 1 | - | -59.08 | -99.9 | - | -92 | -82 | -114 |
| FCF margin | - | -41,025% | -4,818.86% | - | -2,192.21% | -8,945.42% | -421.49% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 7/9/21 | 3/10/22 | 3/1/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.144 | 0.268 | 0.476 | 0.595 | 0.735 | 0.516 | 0.759 | 0.831 | 0.989 | 2.36 | 0.525 | 0.525 | 0.525 | 0.5 | 0.4333 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.66 | -19.96 | -25.85 | -25.98 | -30.97 | -25.82 | -30.84 | -22.9 | -20.7 | -20.45 | -21.31 | -21.28 | -21.91 | -14 | -15.5 |
| Operating Margin | -14,350% | -7,447.39% | -5,431.51% | -4,367.23% | -4,213.2% | -5,003.49% | -4,063.24% | -2,756.08% | -2,092.92% | -866.57% | -4,058.22% | -4,054.13% | -4,174.13% | -2,800% | -3,576.95% |
| Earnings before Tax (EBT) 1 | -20.85 | -20.16 | -25.91 | -25.8 | -30.83 | -25.28 | -29.69 | -22.25 | -20.21 | -20.13 | -20.25 | -19.8 | -19.66 | -13.98 | -15.5 |
| Net income 1 | -20.85 | -20.16 | -25.91 | -25.8 | -30.83 | -25.28 | -29.69 | -22.25 | -20.21 | -20.13 | -20.25 | -19.8 | -19.66 | -13.98 | -15.5 |
| Net margin | -14,481.94% | -7,523.88% | -5,443.7% | -4,335.97% | -4,194.01% | -4,899.03% | -3,911.33% | -2,677.26% | -2,043.88% | -852.92% | -3,857.52% | -3,771.77% | -3,744.04% | -2,795% | -3,576.95% |
| EPS 2 | -0.4400 | -0.4200 | -0.5400 | -0.5400 | -0.6400 | -0.5000 | -0.5400 | -0.4000 | -0.3700 | -0.3600 | -0.3533 | -0.3100 | -0.2850 | -0.2367 | -0.2400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/10/22 | 5/4/22 | 8/4/22 | 11/8/22 | 3/1/23 | 5/4/23 | 8/3/23 | 11/9/23 | 3/28/24 | 5/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 205 | 105 | - | 127 | 30.9 | 114 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -59.1 | -99.9 | - | -92 | -82 | -114 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | 1.38 | - | - | - | - |
| Capex / Sales | - | - | 66.57% | - | - | - | - |
| Announcement Date | 7/9/21 | 3/10/22 | 3/1/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.36
USD
Average target price
11
USD
Spread / Average Target
+366.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.59% | 130M | |
| +29.03% | 48.16B | |
| -0.10% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.48% | 25.59B | |
| -22.74% | 18.96B | |
| +9.06% | 12.92B | |
| +30.01% | 12.03B | |
| -1.51% | 11.77B |
- Stock Market
- Equities
- OMGA Stock
- Financials Omega Therapeutics, Inc.